These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23300030)

  • 21. Modelling of drug disposition kinetics in in vitro intestinal absorption cell models.
    Heikkinen AT; Korjamo T; Mönkkönen J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):180-8. PubMed ID: 20030630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural identifiability and indistinguishability of compartmental models.
    Yates JW; Jones RD; Walker M; Cheung SY
    Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):295-302. PubMed ID: 19331592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global identifiability of linear compartmental models--a computer algebra algorithm.
    Audoly S; D'Angiò L; Saccomani MP; Cobelli C
    IEEE Trans Biomed Eng; 1998 Jan; 45(1):36-47. PubMed ID: 9444838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous optimal experimental design on dose and sample times.
    Nyberg J; Karlsson MO; Hooker AC
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):125-45. PubMed ID: 19319484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.
    Eudy RJ; Riggs MM; Gastonguay MR
    AAPS J; 2015 Sep; 17(5):1280-4. PubMed ID: 26077506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review: To be or not to be an identifiable model. Is this a relevant question in animal science modelling?
    Muñoz-Tamayo R; Puillet L; Daniel JB; Sauvant D; Martin O; Taghipoor M; Blavy P
    Animal; 2018 Apr; 12(4):701-712. PubMed ID: 29096725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of GI conditions critical to oral drug absorption in malnourished children.
    Freerks L; Papadatou Soulou E; Batchelor H; Klein S
    Eur J Pharm Biopharm; 2019 Apr; 137():9-22. PubMed ID: 30735799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimation of parameters for the elimination of an orally administered test substance with unknown absorption.
    Vogt JA; Denzer C
    J Pharmacokinet Pharmacodyn; 2013 Apr; 40(2):177-87. PubMed ID: 23377860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural identifiability of "first-pass" models.
    Venot A; Walter E; Lecourtier Y; Raksanyi A; Chauvelot-Moachon L
    J Pharmacokinet Biopharm; 1987 Apr; 15(2):179-89. PubMed ID: 3612500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models.
    Pilari S; Huisinga W
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):365-405. PubMed ID: 20661651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.
    Jones HM; Gardner IB; Collard WT; Stanley PJ; Oxley P; Hosea NA; Plowchalk D; Gernhardt S; Lin J; Dickins M; Rahavendran SR; Jones BC; Watson KJ; Pertinez H; Kumar V; Cole S
    Clin Pharmacokinet; 2011 May; 50(5):331-47. PubMed ID: 21456633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of new measures of nonlinearity to parameter estimation and simulations in individual pharmacokinetic analyses.
    Khinkis L; Crotzer M
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):43-52. PubMed ID: 30607795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of posture on pharmacokinetics.
    Queckenberg C; Fuhr U
    Eur J Clin Pharmacol; 2009 Feb; 65(2):109-19. PubMed ID: 18936930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifiability and parameter estimation.
    Jacquez JA
    JPEN J Parenter Enteral Nutr; 1991; 15(3):55S-59S. PubMed ID: 1865558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of gastric emptying kinetics on the drug release from enteric coated pellets in fasted state: an in vitro/in vivo correlation.
    Stefanič M; Locatelli I; Vrečer F; Sever T; Mrhar A; Bogataj M
    Eur J Pharm Biopharm; 2012 Oct; 82(2):376-82. PubMed ID: 22884655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An experimental design strategy for quantitating complex pharmacokinetic models: enterohepatic circulation with time-varying gallbladder emptying as an example.
    Wang YM; Reuning RH
    Pharm Res; 1992 Feb; 9(2):169-77. PubMed ID: 1553336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin.
    Hall AJ; Chappell MJ; Aston JA; Ward SA
    Comput Methods Programs Biomed; 2013 Oct; 112(1):1-15. PubMed ID: 23871681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reprint of "Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin".
    Hall AJ; Chappell MJ; Aston JA; Ward SA
    Comput Methods Programs Biomed; 2014 May; 114(3):e14-28. PubMed ID: 24457047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.